envveno medical corp - NVNO

NVNO

Close Chg Chg %
0.34 0.01 3.74%

Pre-Market

0.35

+0.01 (3.74%)

Volume: 273.18K

Last Updated:

Dec 24, 2025, 1:00 PM EDT

Company Overview: envveno medical corp - NVNO

NVNO Key Data

Open

$0.33

Day Range

0.33 - 0.37

52 Week Range

0.30 - 5.61

Market Cap

$6.87M

Shares Outstanding

20.22M

Public Float

19.49M

Beta

1.07

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$1.13

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

502.38K

 

NVNO Performance

1 Week
 
10.87%
 
1 Month
 
-7.48%
 
3 Months
 
-63.38%
 
1 Year
 
-88.74%
 
5 Years
 
-95.53%
 

NVNO Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 1
Full Ratings ➔

About envveno medical corp - NVNO

enVVeno Medical Corp. is a development stage medical device company, which develops tissue based solutions that are designed to be life sustaining or life enhancing for patients with cardiovascular disease, and peripheral arterial and venous disease. Its products include VenoValve and enVVe. The company was founded by Norman Jaffe on December 22, 1999 and is headquartered in Irvine, CA.

NVNO At a Glance

enVVeno Medical Corp.
70 Doppler
Irvine, California 92618
Phone 1-949-261-2900 Revenue 0.00
Industry Medical Specialties Net Income -21,819,000.00
Sector Health Technology Employees 37
Fiscal Year-end 12 / 2025
View SEC Filings

NVNO Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio N/A
Price to Book Ratio 1.256
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -0.415
Enterprise Value to Sales N/A
Total Debt to Enterprise Value 0.11

NVNO Efficiency

Revenue/Employee N/A
Income Per Employee -589,702.703
Receivables Turnover N/A
Total Asset Turnover N/A

NVNO Liquidity

Current Ratio 20.875
Quick Ratio 20.875
Cash Ratio 20.598

NVNO Profitability

Gross Margin N/A
Operating Margin N/A
Pretax Margin N/A
Net Margin N/A
Return on Assets -46.627
Return on Equity -49.387
Return on Total Capital -50.48
Return on Invested Capital -48.42

NVNO Capital Structure

Total Debt to Total Equity 2.524
Total Debt to Total Capital 2.462
Total Debt to Total Assets 2.367
Long-Term Debt to Equity 1.66
Long-Term Debt to Total Capital 1.62
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Envveno Medical Corp - NVNO

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
- - - -
-
Sales Growth
- - - -
-
Cost of Goods Sold (COGS) incl D&A
452.91K 525.00K 546.00K 528.00K
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
452.91K 525.00K 546.00K 528.00K
Depreciation
452.91K 525.00K 546.00K 528.00K
Amortization of Intangibles
- - - -
-
COGS Growth
+17.95% +15.92% +4.00% -3.30%
Gross Income
(452.91K) (525.00K) (546.00K) (528.00K)
Gross Income Growth
-17.95% -15.92% -4.00% +3.30%
Gross Profit Margin
- - - -
-
2021 2022 2023 2024 5-year trend
SG&A Expense
16.44M 24.41M 24.69M 23.30M
Research & Development
5.73M 9.91M 13.58M 12.25M
Other SG&A
10.71M 14.49M 11.11M 11.05M
SGA Growth
+87.86% +48.46% +1.17% -5.65%
Other Operating Expense
- - - -
-
Unusual Expense
(312.70K) (49.00K) (468.00K) 22.00K
EBIT after Unusual Expense
(16.58M) (24.88M) (24.77M) (23.85M)
Non Operating Income/Expense
51.98K 214.00K 1.25M 2.03M
Non-Operating Interest Income
18.71K 161.00K 180.00K 389.00K
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- - - -
-
Interest Expense Growth
- - - -
-
Gross Interest Expense
- - - -
-
Interest Capitalized
- - - -
-
Pretax Income
(16.53M) (24.67M) (23.52M) (21.82M)
Pretax Income Growth
-80.92% -49.26% +4.67% +7.22%
Pretax Margin
- - - -
-
Income Tax
- - - -
-
Income Tax - Current - Domestic
3.60M 5.03M 5.55M 5.42M
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
(3.60M) (5.03M) (5.55M) (5.42M)
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(16.53M) (24.67M) (23.52M) (21.82M)
Minority Interest Expense
- - - -
-
Net Income
(16.53M) (24.67M) (23.52M) (21.82M)
Net Income Growth
-80.92% -49.26% +4.67% +7.22%
Net Margin Growth
- - - -
-
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(16.53M) (24.67M) (23.52M) (21.82M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(16.53M) (24.67M) (23.52M) (21.82M)
EPS (Basic)
-1.9042 -2.1967 -1.9117 -1.2728
EPS (Basic) Growth
+74.76% -15.36% +12.97% +33.42%
Basic Shares Outstanding
8.68M 11.23M 12.30M 17.14M
EPS (Diluted)
-1.9042 -2.1967 -1.9117 -1.2728
EPS (Diluted) Growth
+74.76% -15.36% +12.97% +33.42%
Diluted Shares Outstanding
8.68M 11.23M 12.30M 17.14M
EBITDA
(16.44M) (24.41M) (24.69M) (23.30M)
EBITDA Growth
-87.86% -48.46% -1.17% +5.65%
EBITDA Margin
- - - -
-

Insider Actions for Envveno Medical Corp - NVNO

Date Name Shares Transaction Value
May 21, 2025 Jennifer Brighton Chief Financial Officer 350,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Envveno Medical Corp in the News